Is your social strategy ready for what's next in 2025?

HubSpot Media's latest Social Playbook reveals what's actually working for over 1,000 global marketing leaders across TikTok, Instagram, LinkedIn, Pinterest, Facebook, and YouTube.

Inside this comprehensive report, you’ll discover:

Unlock the playbook—free when you subscribe to the Masters in Marketing newsletter.

Get cutting-edge insights, twice a week, from the marketing leaders shaping the future.

Download The Report

New to LEVITY? Start here! Want to know more about who’s behind LEVITY? Check out this page. 🙏🏼 Not subscribed to the LEVITY podcast on Youtube yet? Do it here. 🎧 More of a listener? The podcast is also available on Spotify, Apple Podcasts and other places.

Modern longevity science has poured much attention, resources, and capital into epigenetics. On one side sit biological age clocks - hopeful contenders as future biomarkers. On the other is the regenerative allure of partial reprogramming with the Yamanaka factors.

But, as it turns out, the landscape is wider than that.

Biotech startup General Control, with $5.5 million in funding secured from age1 and Fifty Years, came out of stealth a few days ago, introduced to the world through an Ashlee Vance exclusive over at Core Memory. At the first mention of “epigenetic,” I assumed I knew where this was headed: another contestant in the partial reprogramming race. It isn’t. Or rather, it’s something different from what that word has come to mean in the longevity space.

We’ll get to General Control’s vision in a bit. First, it’s worth paying attention to who’s behind it, because that’s also part of what makes this company different.

Lada Nuzhna, the founder and CEO at General Control, is not a newcomer to aging science. She entered the field early in her life (Nuzhna is still only 26). In 2021 she won a Thiel Fellowship, and co-founded Impetus Grants, a private-philanthropy experiment that pushed millions into aging biology with almost no bureaucracy. It became the funding source researchers applied to when traditional committees waved them away. Prospect magazine described her as “one of the most influential people in the field of longevity.”

When people raise the familiar philosophical objections - death as life’s great curator, the notion that more healthy years would dilute meaning bla bla bla - she answers with a distinctly LEVITY-compatible line: “If you died at 15, would it seem like the most amazing life you could ever live?”

Yes, she’s got her priorities straight.

So, General Control.

To understand its place in the ecosystem, one can juxtapose it with partial reprogramming.

Reprogramming involves pulsing cells with a subset of the Yamanaka factors (often OCT4, SOX2, and KLF4). It is a global, somewhat mysterious operation. You introduce these master regulators, and they remodel thousands of loci* across the genome. All of a sudden gene expressions look and behave “younger”.

* A locus is a specific, fixed position on a chromosome where a particular gene or genetic marker is located.

A whole ecosystem of companies - Altos Labs, NewLimit, Life Bio, and others - is effectively betting that this emergent, system-wide reset can be made safe for humans.

General Control offers a different philosophy: do it locally, not globally. And don’t reprogram, but edit.

Instead of whispering to the whole epigenome, you send an editor to one address and say “this gene should be louder”, or to another and say “this one should be permanently quiet”.

General Control argues that you can achieve significant therapeutic benefit by explicitly designing the network yourself - turning specific metabolic genes up in the liver or dialing down inflammatory pathways in adipose tissue. If reprogramming is a systemic nudge, epigenetic editing is explicit command and control.

To call the company ambitious is an understatement. The aim is to build therapies that can “upregulate or downregulate any gene, to any level and in any combination”.

The company utilizes tools that resemble the famous CRISPR, yet with an important distinction: they do not cut the DNA. Instead, these molecular machines - what General Control describes as “synthetic transcription factors” - park themselves on a chosen regulatory site, a locus adjacent to a gene. Once docked, their effector domains act like a dimmer switch, either opening the chromatin* to amplify the gene’s volume or cinching it tight to silence it.

* Chromatin is DNA wrapped around proteins. How tightly it’s wrapped strongly influences which genes are turned on or off.

The strategy is combinatorial. By bundling several of these editors into a single therapy, General Control aims to adjust small, intricate networks of genes simultaneously - tweaking a metabolic pathway in the liver, for instance, or a stress response in muscle.

Their early pipeline reflects this precision: three programs in obesity, liver fibrosis, and muscle function - two gene-silencing plays and one activation program. In obesity and liver disease, they aim to shut down specific drivers of fat distribution and fibrosis; in muscle, they are trying to turn age-dimmed maintenance genes back up.

Perhaps the strongest market signal that this isn’t merely theoretical is the company’s partnership with Novo Nordisk. The Danish pharmaceutical giant, currently reshaping the world (and, quite literally, its inhabitants) with Ozempic and Wegovy, does not sign partnership deals out of charity. They are hunting for “post-GLP-1” modalities and by partnering with General Control, Novo is effectively signaling that programmable epigenetic activation is a credible contender for the next generation of metabolic medicine.

General Control also draws a sharp contrast with RNA interference (RNAi) and antisense oligonucleotides (ASOs). These existing technologies work by intercepting messenger RNA and preventing it from becoming protein. While precise and effective, they suffer from a brutal practical flaw: they wash out. To keep a gene suppressed, a patient requires chronic dosing for life.

General Control proposes that chromatin-level silencing can collapse that burden into a “one-and-done” (or at least very infrequent) intervention. By laying down repressive epigenetic marks at the promoter locus, the gene could stay off for years without the constant presence of a drug. For a 65-year-old managing three comorbidities, the difference between a weekly or monthly injection and a reset once every decade is profound.

So, what has made General Control’s approach possible? Why is this happening now? Why not ten years ago? The answer lies in the convergence of three specific preconditions.

The Tools: Reliable gene editors are a recent invention. Early iterations were clumsy and large; only recently have we developed compact, modular effectors potent enough to be therapeutic candidates.

The Maps: To design a program for “old liver,” you need a wiring diagram. The explosion in the scale and resolution of single-cell transcriptomics and chromatin accessibility maps over the last five years has finally allowed scientists to move from educated guesswork to data-driven decisions about which knobs to turn.

The Precedent: General Control is not operating in a vacuum. Companies like nChroma Bio, Tune Therapeutics, and Omega Therapeutics have already convinced regulators to let them test locus-targeted epigenetic editors in humans, on the back of durable gene-silencing data in animals. While these companies are not focused on aging, they have done the heavy lifting of de-risking the modality.

Ultimately, General Control is not trying to render partial reprogramming obsolete. Rather, it is carving out a parallel lane.

If aging is a problem of transcriptional drift and network failure, the future likely belongs to a hybrid approach. We may look back on this era and see reprogramming as the high-leverage, system-level reset, while locus-specific editing serves as the fine-tuning layer - the precise tool that locks desirable states in place and corrects specific disease networks.

Lada Nuzhna and General Control are betting that they can own that fine-tuning layer. Here’s hoping they succeed.